- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Diplomat becomes distributor of recently approved cancer drug
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
SILVER SPRING, Md. — The safety of silicone breast implants has long been a subject of controversy, but a review by the Food and Drug Administration indicated another possible health risk.
The FDA said Thursday that it had found a possible association between saline and silicone gel-filled breast implants and a rare cancer called anaplastic large-cell lymphoma, and that patients with implants may have a “very small but significant” risk of ALCL in the scar capsule adjacent to the implant.
The agency is requesting reports of any confirmed cases of ALCL in women with breast implants and said it was working with manufacturers to update product labeling.